☰

Anahita R. Dastur, Ph.D. - Publications

Affiliations: 
2007 Cell and Molecular Biology University of Texas at Austin, Austin, Texas, U.S.A. 
Area:
Molecular Biology, Cell Biology
Tree Info Grants Similar researchers PubMed Report error

21 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Wang Y, Zhang L, Wei Y, Huang W, Li L, Wu AA, Dastur A, Greninger P, Bray WM, Zhang CS, Li M, Lian W, Hu Z, Wang X, Liu G, et al. Pharmacological Targeting of Vacuolar H-ATPase via Subunit V1G Combats Multidrug-Resistant Cancer. Cell Chemical Biology. PMID 32649904 DOI: 10.1016/J.Chembiol.2020.06.011  0.404
2018 Dastur A, Choi A, Costa C, Yin X, Williams AF, McClanaghan JD, Greenberg M, Roderick JE, Patel NU, Boisvert JL, McDermott U, Garnett MJ, Almenara J, Grant S, Rizzo K, et al. NOTCH1 represses MCL-1 levels in GSI-resistant T-ALL, making them susceptible to ABT-263. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30224339 DOI: 10.1158/1078-0432.Ccr-18-0867  0.302
2017 Kodack DP, Farago AF, Dastur A, Held MA, Dardaei L, Friboulet L, von Flotow F, Damon LJ, Lee D, Parks M, Dicecca R, Greenberg M, Kattermann KE, Riley AK, Fintelmann FJ, et al. Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care. Cell Reports. 21: 3298-3309. PMID 29241554 DOI: 10.1016/J.Celrep.2017.11.051  0.318
2016 Ham J, Costa C, Sano R, Lochmann TL, Sennott EM, Patel NU, Dastur A, Gomez-Caraballo M, Krytska K, Hata AN, Floros KV, Hughes MT, Jakubik CT, Heisey DA, Ferrell JT, et al. Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination. Cancer Cell. 29: 159-72. PMID 26859456 DOI: 10.1016/J.Ccell.2016.01.002  0.335
2016 Dastur A, Costa C, Faber A, Benes C. Abstract 3846: Sensitivity of NOTCH1 mutant T-ALL to ABT-263 Cancer Research. 76: 3846-3846. DOI: 10.1158/1538-7445.Am2016-3846  0.384
2015 Faber AC, Farago AF, Costa C, Dastur A, Gomez-Caraballo M, Robbins R, Wagner BL, Rideout WM, Jakubik CT, Ham J, Edelman EJ, Ebi H, Yeo AT, Hata AN, Song Y, et al. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 112: E1288-96. PMID 25737542 DOI: 10.1073/Pnas.1411848112  0.403
2015 Chen L, Dastur A, Yin X, Benes C. Abstract A27: Transposon mutagenesis screen identifies genes conferring resistance to BRAF inhibition in melanoma Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-A27  0.369
2015 Dastur A, Faber A, Costa C, Benes C. Abstract A77: Repression of mTORC1 activity in NOTCH1 mutant T-ALL results in sensitivity to the BCL-2 inhibitor ABT-263 Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A77  0.409
2014 Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, Dastur A, Amzallag A, Ramaswamy S, Tesar B, Jenkins CE, Hannett NM, McMillin D, Sanda T, Sim T, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 511: 616-20. PMID 25043025 DOI: 10.1038/Nature13393  0.401
2014 Faber AC, Coffee EM, Costa C, Dastur A, Ebi H, Hata AN, Yeo AT, Edelman EJ, Song Y, Tam AT, Boisvert JL, Milano RJ, Roper J, Kodack DP, Jain RK, et al. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discovery. 4: 42-52. PMID 24163374 DOI: 10.1158/2159-8290.Cd-13-0315  0.404
2014 Dastur A, Benes C. Abstract 5523: Study of the response of melanoma lines to BRAF/MEK inhibitors and combination drug treatments Cancer Research. 74: 5523-5523. DOI: 10.1158/1538-7445.Am2014-5523  0.414
2014 Faber AC, Costa C, Dastur A, Benes C, Engelman J. Abstract 2933: Assessment of ABT-263 activity across a comprehensive cancer cell line collection leads to a novel, potent combination therapy for small cell lung cancer Cancer Research. 74: 2933-2933. DOI: 10.1158/1538-7445.Am2014-2933  0.396
2013 Chen L, Stuart L, Ohsumi TK, Burgess S, Varshney GK, Dastur A, Borowsky M, Benes C, Lacy-Hulbert A, Schmidt EV. Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeutics. Bmc Cancer. 13: 93. PMID 23442791 DOI: 10.1186/1471-2407-13-93  0.365
2013 Fallahi-Sichani M, Moerke NJ, Dastur A, Benes CH, Sorger PK. Abstract 5213: A systems biology approach to understanding differential phenotypic outcome of BRAF(V600E) inhibition in melanoma cells. Cancer Research. 73: 5213-5213. DOI: 10.1158/1538-7445.Am2013-5213  0.414
2013 Coffee EM, Faber AC, Costa C, Dastur A, Ebi H, Hata AN, Yeo AT, J E, Song Y, Tam AT, Boisvert JL, Milano RJ, Roper J, Kodack DP, Jain RK, et al. Abstract C263: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C263  0.415
2013 Chen L, Dastur A, Benes C. Abstract C201: Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeutics. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C201  0.389
2013 Dastur A, Benes C. Abstract B136: Study of the response of melanoma lines to BRAF/MEK inhibitors and combination drug treatments. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B136  0.417
2012 Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 483: 570-5. PMID 22460902 DOI: 10.1038/Nature11005  0.407
2006 Dastur A, Beaudenon S, Kelley M, Krug RM, Huibregtse JM. Herc5, an interferon-induced HECT E3 enzyme, is required for conjugation of ISG15 in human cells. The Journal of Biological Chemistry. 281: 4334-8. PMID 16407192 DOI: 10.1074/Jbc.M512830200  0.568
2005 Beaudenon S, Dastur A, Huibregtse JM. Expression and assay of HECT domain ligases. Methods in Enzymology. 398: 112-25. PMID 16275324 DOI: 10.1016/S0076-6879(05)98011-7  0.56
2004 Salvat C, Wang G, Dastur A, Lyon N, Huibregtse JM. The -4 phenylalanine is required for substrate ubiquitination catalyzed by HECT ubiquitin ligases. The Journal of Biological Chemistry. 279: 18935-43. PMID 14966115 DOI: 10.1074/Jbc.M312201200  0.558
Show low-probability matches.